ALK-Abelló A/S (ALK-B.CO)
DKK 155.8
(1.7%)
DKK 155.8
(1.7%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.82 Billion DKK | 6.94% |
| 2022 | 4.51 Billion DKK | 15.19% |
| 2021 | 3.91 Billion DKK | 12.17% |
| 2020 | 3.49 Billion DKK | 6.63% |
| 2019 | 3.27 Billion DKK | 12.32% |
| 2018 | 2.91 Billion DKK | 0.17% |
| 2017 | 2.91 Billion DKK | -3.16% |
| 2016 | 3 Billion DKK | 16.97% |
| 2015 | 2.56 Billion DKK | 5.59% |
| 2014 | 2.43 Billion DKK | 8.42% |
| 2013 | 2.24 Billion DKK | -4.31% |
| 2012 | 2.34 Billion DKK | -0.13% |
| 2011 | 2.34 Billion DKK | 9.72% |
| 2010 | 2.14 Billion DKK | 10.59% |
| 2009 | 1.93 Billion DKK | 8.46% |
| 2008 | 1.78 Billion DKK | 7.99% |
| 2007 | 1.65 Billion DKK | 10.95% |
| 2006 | 1.48 Billion DKK | 22.35% |
| 2005 | 1.21 Billion DKK | 0.0% |
| 2004 | - DKK | 0.0% |
| 2003 | - DKK | 0.0% |
| 2002 | - DKK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.35 Billion DKK | 0.45% |
| 2024 Q2 | 1.37 Billion DKK | 1.7% |
| 2023 Q2 | 1.13 Billion DKK | -8.02% |
| 2023 Q1 | 1.23 Billion DKK | -1.2% |
| 2023 Q3 | 1.11 Billion DKK | -2.2% |
| 2023 FY | 4.82 Billion DKK | 6.94% |
| 2023 Q4 | 1.34 Billion DKK | 21.17% |
| 2022 FY | 4.51 Billion DKK | 15.19% |
| 2022 Q2 | 1.04 Billion DKK | -9.52% |
| 2022 Q3 | 1.06 Billion DKK | 1.63% |
| 2022 Q4 | 1.24 Billion DKK | 17.61% |
| 2022 Q1 | 1.15 Billion DKK | 5.1% |
| 2021 Q3 | 928 Million DKK | 6.91% |
| 2021 Q4 | 1.09 Billion DKK | 18.43% |
| 2021 Q1 | 1.02 Billion DKK | 3.03% |
| 2021 FY | 3.91 Billion DKK | 12.17% |
| 2021 Q2 | 868 Million DKK | -14.99% |
| 2020 Q4 | 991 Million DKK | 28.37% |
| 2020 Q1 | 956 Million DKK | 8.27% |
| 2020 Q2 | 772 Million DKK | -19.25% |
| 2020 Q3 | 772 Million DKK | 0.0% |
| 2020 FY | 3.49 Billion DKK | 6.63% |
| 2019 Q4 | 883 Million DKK | 19.49% |
| 2019 FY | 3.27 Billion DKK | 12.32% |
| 2019 Q1 | 867 Million DKK | 10.17% |
| 2019 Q2 | 785 Million DKK | -9.46% |
| 2019 Q3 | 739 Million DKK | -5.86% |
| 2018 Q2 | 715 Million DKK | -4.92% |
| 2018 Q4 | 787 Million DKK | 17.99% |
| 2018 Q1 | 752 Million DKK | -1.44% |
| 2018 FY | 2.91 Billion DKK | 0.17% |
| 2018 Q3 | 667 Million DKK | -6.71% |
| 2017 Q3 | 667 Million DKK | -3.47% |
| 2017 FY | 2.91 Billion DKK | -3.16% |
| 2017 Q4 | 763 Million DKK | 14.39% |
| 2017 Q2 | 691 Million DKK | -12.42% |
| 2017 Q1 | 789 Million DKK | 4.64% |
| 2016 Q4 | 754 Million DKK | 19.68% |
| 2016 FY | 3 Billion DKK | 16.97% |
| 2016 Q1 | 848 Million DKK | 23.44% |
| 2016 Q2 | 773 Million DKK | -8.84% |
| 2016 Q3 | 630 Million DKK | -18.5% |
| 2015 FY | 2.56 Billion DKK | 5.59% |
| 2015 Q3 | 667 Million DKK | 18.05% |
| 2015 Q1 | 650 Million DKK | 6.21% |
| 2015 Q4 | 687 Million DKK | 3.0% |
| 2015 Q2 | 565 Million DKK | -13.08% |
| 2014 Q3 | 522 Million DKK | -15.12% |
| 2014 Q4 | 612 Million DKK | 17.24% |
| 2014 FY | 2.43 Billion DKK | 8.42% |
| 2014 Q1 | 684 Million DKK | 15.35% |
| 2014 Q2 | 615 Million DKK | -10.09% |
| 2013 Q3 | 509 Million DKK | -4.32% |
| 2013 Q4 | 593 Million DKK | 16.5% |
| 2013 FY | 2.24 Billion DKK | -4.31% |
| 2013 Q1 | 610 Million DKK | -0.81% |
| 2013 Q2 | 532 Million DKK | -12.79% |
| 2012 FY | 2.34 Billion DKK | -0.13% |
| 2012 Q4 | 615 Million DKK | 1.15% |
| 2012 Q2 | 515 Million DKK | -15.16% |
| 2012 Q1 | 607 Million DKK | 5.02% |
| 2012 Q3 | 608 Million DKK | 18.06% |
| 2011 FY | 2.34 Billion DKK | 9.72% |
| 2011 Q3 | 519 Million DKK | 8.81% |
| 2011 Q1 | 609 Million DKK | -18.47% |
| 2011 Q4 | 578 Million DKK | 11.37% |
| 2011 Q2 | 477 Million DKK | -21.67% |
| 2010 Q3 | 518 Million DKK | 8.6% |
| 2010 Q1 | 558 Million DKK | 46.07% |
| 2010 Q2 | 477 Million DKK | -14.52% |
| 2010 FY | 2.14 Billion DKK | 10.59% |
| 2010 Q4 | 747 Million DKK | 44.21% |
| 2009 Q4 | 382 Million DKK | -18.03% |
| 2009 Q1 | 493 Million DKK | 0.0% |
| 2009 Q3 | 466 Million DKK | 7.37% |
| 2009 Q2 | 434 Million DKK | -11.97% |
| 2009 FY | 1.93 Billion DKK | 8.46% |
| 2008 FY | 1.78 Billion DKK | 7.99% |
| 2007 FY | 1.65 Billion DKK | 10.95% |
| 2006 FY | 1.48 Billion DKK | 22.35% |
| 2005 FY | 1.21 Billion DKK | 0.0% |
| 2004 FY | - DKK | 0.0% |
| 2003 FY | - DKK | 0.0% |
| 2002 FY | - DKK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bavarian Nordic A/S | 7.05 Billion DKK | 31.645% |
| Genmab A/S | 16.47 Billion DKK | 70.717% |
| Gubra A/S | 205 Million DKK | -2253.113% |
| Novo Nordisk A/S | 232.26 Billion DKK | 97.923% |
| Orphazyme A/S | - DKK | -Infinity% |
| Pharma Equity Group A/S | - DKK | -Infinity% |
| Zealand Pharma A/S | 342.78 Million DKK | -1307.284% |